Merck (MRK) FCF Margin (2009 - 2026)
Merck (MRK) reported FCF Margin of 17.97% for Q1 2026, up 1043.0% year-over-year from 1.57% in Q1 2025, and up 61.59% on a QoQ basis from 11.12% in Q4 2025.
Merck (MRK) has 18 years of FCF Margin data on file, last reported at 17.97% in Q1 2026.
- Quarterly FCF Margin rose 1043.0% year-over-year to 17.97% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21.46% (down 519.0% YoY) and the FY2025 annual result came in at 19.01%, down 919.0% from the prior year.
- FCF Margin improved to 17.97% in Q1 2026 per MRK's latest filing, from 11.12% in the prior quarter.
- Across five years, FCF Margin topped out at 51.08% in Q3 2024 and bottomed at 5.08% in Q4 2023.
- The 5-year median for FCF Margin is 18.22% (2023), against an average of 21.23%.
- The widest annual swing landed in 2022, when FCF Margin jumped 2227 bps; it then sank 2880 bps in 2023.
- Tracing MRK's FCF Margin over 5 years: stood at 23.72% in 2022, then tumbled by 121 bps to 5.08% in 2023, then surged by 417 bps to 16.08% in 2024, then tumbled by 31 bps to 11.12% in 2025, then soared by 62 bps to 17.97% in 2026.
- Per Business Quant, the three latest MRK FCF Margin figures stand at 17.97% (Q1 2026), 11.12% (Q4 2025), and 39.56% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 15.19% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 6.09% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 23.76% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | 17.97% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 17.14% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 34.87% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 93.16% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 6.59% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.97% |
| Dec 31, 2025 | 11.12% |
| Sep 30, 2025 | 39.56% |
| Jun 30, 2025 | 16.00% |
| Mar 31, 2025 | 7.55% |
| Dec 31, 2024 | 16.08% |
| Sep 30, 2024 | 51.08% |
| Jun 30, 2024 | 30.08% |
| Mar 31, 2024 | 14.13% |
| Dec 31, 2023 | -5.08% |
| Sep 30, 2023 | 42.70% |
| Jun 30, 2023 | 18.22% |
| Mar 31, 2023 | 2.29% |
| Dec 31, 2022 | 23.72% |
| Sep 30, 2022 | 29.92% |
| Jun 30, 2022 | 21.74% |
| Mar 31, 2022 | 23.75% |
| Dec 31, 2021 | 28.75% |
| Sep 30, 2021 | 27.56% |
| Jun 30, 2021 | 8.81% |
| Mar 31, 2021 | 1.49% |
| Dec 31, 2020 | 18.08% |
| Sep 30, 2020 | 11.71% |
| Jun 30, 2020 | 14.44% |
| Mar 31, 2020 | -2.31% |
| Dec 31, 2019 | -19.16% |
| Sep 30, 2019 | 26.35% |
| Jun 30, 2019 | 19.57% |
| Mar 31, 2019 | 6.85% |
| Dec 31, 2018 | 24.21% |
| Sep 30, 2018 | 19.83% |
| Jun 30, 2018 | 26.75% |
| Mar 31, 2018 | 7.02% |
| Dec 31, 2017 | 31.67% |
| Sep 30, 2017 | -15.61% |
| Jun 30, 2017 | 29.45% |
| Mar 31, 2017 | -0.56% |
| Dec 31, 2016 | 30.46% |
| Sep 30, 2016 | 24.32% |
| Jun 30, 2016 | 12.44% |
| Mar 31, 2016 | 20.34% |
| Dec 31, 2015 | 36.74% |
| Sep 30, 2015 | 29.73% |
| Jun 30, 2015 | 24.79% |
| Mar 31, 2015 | 22.08% |
| Dec 31, 2014 | -14.55% |
| Sep 30, 2014 | 38.15% |
| Jun 30, 2014 | 18.41% |
| Mar 31, 2014 | 21.01% |
| Dec 31, 2013 | 22.94% |
| Sep 30, 2013 | 32.58% |
| Jun 30, 2013 | 17.48% |
| Mar 31, 2013 | 18.65% |
| Dec 31, 2012 | 8.78% |
| Sep 30, 2012 | 23.72% |
| Jun 30, 2012 | 20.22% |
| Mar 31, 2012 | 15.54% |
| Dec 31, 2011 | 21.39% |
| Sep 30, 2011 | 34.49% |
| Jun 30, 2011 | 20.47% |
| Mar 31, 2011 | 12.06% |
| Dec 31, 2010 | 23.81% |
| Sep 30, 2010 | 20.26% |
| Jun 30, 2010 | 26.34% |
| Mar 31, 2010 | 8.96% |
| Dec 31, 2009 | 16.70% |
| Sep 30, 2009 | -10.17% |
| Jun 30, 2009 | 6.51% |
| Mar 31, 2009 | 8.87% |